Company intelligence / Profile preview

EPS Group

Shinjuku-ku, Tokyo, Japanepsgroupinc.com ↗

Ownership: Private
Development stage: Other

Overview

Internal programs are early stage; FEF Pharmaceutical Co., Ltd. has candidates entering Phase I/II investigator-led trials. Extensive track record in oncology/CNS/cardiovascular/post-marketing studies as CRO.

Therapeutic areas: OncologyRare DiseasesCardiovascularNeurologyInfectious Diseases
Modalities: Small moleculesRegenerative medicine/cell therapyGene therapyBiologics/mAbs
Industry: Biotech

Partnerships

Collaborates with medical institutions across Japan and Chinapartnerships with Suzuken CO LTD on EKISHIN business in China

Beyond the preview

Go deeper on EPS Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EPS Group.

Explore the full profile